ARS Pharmaceuticals, Inc. — Director's Dealing 2024

Aug 22, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-08-20

Reporting Person: Scott Kathleen D. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-20	Common Stock	M	12500	$1.50	Acquired	25699	Direct
2024-08-20	Common Stock	S	12500	$16	Disposed	13199	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-08-20	Stock Option (Right to Buy)	$1.50	M	12500	Disposed	2032-02-29	Common Stock (12500)	Direct

Footnotes

F1: Includes 2,969 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on June 30, 2023 and 1,980 shares acquired under the ESPP on June 28, 2024.

F2: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2024.

F3: Immediately exercisable.